Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs
Aims Available bacterins, commercial or autogenous, for Actinobacillus pleuropneumoniae disease control have, thus far, shown debatable protective efficacy and only in homologous challenges. Our study sought to determine whether the addition of reombinant protein ApxIV to the multicomponent vaccine...
Gespeichert in:
| Veröffentlicht in: | Journal of applied microbiology 2018-06, Vol.124 (6), p.1366-1376 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1376 |
|---|---|
| container_issue | 6 |
| container_start_page | 1366 |
| container_title | Journal of applied microbiology |
| container_volume | 124 |
| creator | Wu, H.‐C. Yeh, P.‐H. Hsueh, K.‐J. Yang, W.‐J. Chu, C.‐Y. |
| description | Aims
Available bacterins, commercial or autogenous, for Actinobacillus pleuropneumoniae disease control have, thus far, shown debatable protective efficacy and only in homologous challenges. Our study sought to determine whether the addition of reombinant protein ApxIV to the multicomponent vaccine could enhance protection against homologous and heterologous challenge of A. pleuropneumoniae.
Methods and Results
The virulence of ApxI, ApxII, ApxIV and OMP were cloned and expressed using a prokaryotic system; these recombinant proteins were combined with inactivated A. pleuropneumoniae serovar 1 to formulate different multicomponent vaccines. Immune response and protective efficacy of the vaccines were evaluated in mice and pigs. A protection rate of 67% was observed against heterologous challenge in mice vaccinated with the rApxIV formulation. Piglets vaccinated with vaccine containing ApxIV produced significantly higher antibody titre and provided complete protection and reduced gross lesions by 67% when compared with the nonimmunized group after homologous challenge. Additionally, flow cytometry analysis showed significant cellular immune response.
Conclusions
The results of our vaccination experiments revealed that a combination of inactivated bacteria and the recombinant antigens rApxI, rApxII, rApxIV and rOMP can provide effective protection against heterologous A. pleuropneumoniae challenge.
Significance and Impact of the Study
The addition of ApxIV to the multicomponent vaccine could enhance homologous and heterologous protection in mice and pigs, respectively, against challenge by A. pleuropneumoniae. |
| doi_str_mv | 10.1111/jam.13726 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2001408418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2036673678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-9eb19549aa45fe807d4f035c7dbcc945c65fde7926e521b13b8442575f1d31af3</originalsourceid><addsrcrecordid>eNp1kU1LxDAQhoMofh_8A1LwoodqvrM9LoufKIKo15KmE83SJrXZqvvvjVY9COYyYXjmYZgXoT2Cj0l6J3PdHhOmqFxBm4RJkVOp6OrXn-cCK7qBtmKcY0wYFnIdbdCCM0K53EThDkxoK-e1X2TT7v3yMev6sADnM_DP2huIY8Ms3CtkYK0z2iwz_aSdj2kk9X2otHFNMyS0gaEPnYehDd5pyJKndQYy7eusc09xB61Z3UTY_a7b6OHs9H52kV_fnl_Opte5YYLJvICKFIIXWnNhYYJVzS1mwqi6Mqbgwkhha1AFlSAoqQirJpxToYQlNSPasm10OHrT8i8DxEXZumigabSHMMSSpmNwPOFkktCDP-g8DL1P2yWKSamYVJ_U0UiZPsTYgy273rW6X5YEl58plCmF8iuFxO5_G4eqhfqX_Dl7Ak5G4M01sPzfVF5Nb0blB4nykcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2036673678</pqid></control><display><type>article</type><title>Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Wu, H.‐C. ; Yeh, P.‐H. ; Hsueh, K.‐J. ; Yang, W.‐J. ; Chu, C.‐Y.</creator><creatorcontrib>Wu, H.‐C. ; Yeh, P.‐H. ; Hsueh, K.‐J. ; Yang, W.‐J. ; Chu, C.‐Y.</creatorcontrib><description>Aims
Available bacterins, commercial or autogenous, for Actinobacillus pleuropneumoniae disease control have, thus far, shown debatable protective efficacy and only in homologous challenges. Our study sought to determine whether the addition of reombinant protein ApxIV to the multicomponent vaccine could enhance protection against homologous and heterologous challenge of A. pleuropneumoniae.
Methods and Results
The virulence of ApxI, ApxII, ApxIV and OMP were cloned and expressed using a prokaryotic system; these recombinant proteins were combined with inactivated A. pleuropneumoniae serovar 1 to formulate different multicomponent vaccines. Immune response and protective efficacy of the vaccines were evaluated in mice and pigs. A protection rate of 67% was observed against heterologous challenge in mice vaccinated with the rApxIV formulation. Piglets vaccinated with vaccine containing ApxIV produced significantly higher antibody titre and provided complete protection and reduced gross lesions by 67% when compared with the nonimmunized group after homologous challenge. Additionally, flow cytometry analysis showed significant cellular immune response.
Conclusions
The results of our vaccination experiments revealed that a combination of inactivated bacteria and the recombinant antigens rApxI, rApxII, rApxIV and rOMP can provide effective protection against heterologous A. pleuropneumoniae challenge.
Significance and Impact of the Study
The addition of ApxIV to the multicomponent vaccine could enhance homologous and heterologous protection in mice and pigs, respectively, against challenge by A. pleuropneumoniae.</description><identifier>ISSN: 1364-5072</identifier><identifier>EISSN: 1365-2672</identifier><identifier>DOI: 10.1111/jam.13726</identifier><identifier>PMID: 29431246</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Actinobacillus Infections - immunology ; Actinobacillus Infections - microbiology ; Actinobacillus Infections - prevention & control ; Actinobacillus Infections - veterinary ; Actinobacillus pleuropneumoniae ; Actinobacillus pleuropneumoniae - genetics ; Actinobacillus pleuropneumoniae - immunology ; Animals ; Antibodies, Bacterial - immunology ; Antigens ; Bacterial Proteins - administration & dosage ; Bacterial Proteins - genetics ; Bacterial Proteins - immunology ; Bacterial Vaccines - administration & dosage ; Bacterial Vaccines - genetics ; Bacterial Vaccines - immunology ; Bacterins ; Combined vaccines ; Cytometry ; Disease control ; diseases ; Effectiveness ; Female ; Flow cytometry ; Homology ; Immune response ; Immune response (cell-mediated) ; Immune system ; Lesions ; Mice ; Outer membrane proteins ; Proteins ; recombinant protein ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; Swine ; Swine Diseases - immunology ; Swine Diseases - microbiology ; Swine Diseases - prevention & control ; toxins ; Vaccination ; Vaccines ; Virulence</subject><ispartof>Journal of applied microbiology, 2018-06, Vol.124 (6), p.1366-1376</ispartof><rights>2018 The Society for Applied Microbiology</rights><rights>2018 The Society for Applied Microbiology.</rights><rights>Copyright © 2018 The Society for Applied Microbiology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-9eb19549aa45fe807d4f035c7dbcc945c65fde7926e521b13b8442575f1d31af3</citedby><cites>FETCH-LOGICAL-c3536-9eb19549aa45fe807d4f035c7dbcc945c65fde7926e521b13b8442575f1d31af3</cites><orcidid>0000-0002-5625-8815</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjam.13726$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjam.13726$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29431246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, H.‐C.</creatorcontrib><creatorcontrib>Yeh, P.‐H.</creatorcontrib><creatorcontrib>Hsueh, K.‐J.</creatorcontrib><creatorcontrib>Yang, W.‐J.</creatorcontrib><creatorcontrib>Chu, C.‐Y.</creatorcontrib><title>Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs</title><title>Journal of applied microbiology</title><addtitle>J Appl Microbiol</addtitle><description>Aims
Available bacterins, commercial or autogenous, for Actinobacillus pleuropneumoniae disease control have, thus far, shown debatable protective efficacy and only in homologous challenges. Our study sought to determine whether the addition of reombinant protein ApxIV to the multicomponent vaccine could enhance protection against homologous and heterologous challenge of A. pleuropneumoniae.
Methods and Results
The virulence of ApxI, ApxII, ApxIV and OMP were cloned and expressed using a prokaryotic system; these recombinant proteins were combined with inactivated A. pleuropneumoniae serovar 1 to formulate different multicomponent vaccines. Immune response and protective efficacy of the vaccines were evaluated in mice and pigs. A protection rate of 67% was observed against heterologous challenge in mice vaccinated with the rApxIV formulation. Piglets vaccinated with vaccine containing ApxIV produced significantly higher antibody titre and provided complete protection and reduced gross lesions by 67% when compared with the nonimmunized group after homologous challenge. Additionally, flow cytometry analysis showed significant cellular immune response.
Conclusions
The results of our vaccination experiments revealed that a combination of inactivated bacteria and the recombinant antigens rApxI, rApxII, rApxIV and rOMP can provide effective protection against heterologous A. pleuropneumoniae challenge.
Significance and Impact of the Study
The addition of ApxIV to the multicomponent vaccine could enhance homologous and heterologous protection in mice and pigs, respectively, against challenge by A. pleuropneumoniae.</description><subject>Actinobacillus Infections - immunology</subject><subject>Actinobacillus Infections - microbiology</subject><subject>Actinobacillus Infections - prevention & control</subject><subject>Actinobacillus Infections - veterinary</subject><subject>Actinobacillus pleuropneumoniae</subject><subject>Actinobacillus pleuropneumoniae - genetics</subject><subject>Actinobacillus pleuropneumoniae - immunology</subject><subject>Animals</subject><subject>Antibodies, Bacterial - immunology</subject><subject>Antigens</subject><subject>Bacterial Proteins - administration & dosage</subject><subject>Bacterial Proteins - genetics</subject><subject>Bacterial Proteins - immunology</subject><subject>Bacterial Vaccines - administration & dosage</subject><subject>Bacterial Vaccines - genetics</subject><subject>Bacterial Vaccines - immunology</subject><subject>Bacterins</subject><subject>Combined vaccines</subject><subject>Cytometry</subject><subject>Disease control</subject><subject>diseases</subject><subject>Effectiveness</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Homology</subject><subject>Immune response</subject><subject>Immune response (cell-mediated)</subject><subject>Immune system</subject><subject>Lesions</subject><subject>Mice</subject><subject>Outer membrane proteins</subject><subject>Proteins</subject><subject>recombinant protein</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - immunology</subject><subject>Swine</subject><subject>Swine Diseases - immunology</subject><subject>Swine Diseases - microbiology</subject><subject>Swine Diseases - prevention & control</subject><subject>toxins</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Virulence</subject><issn>1364-5072</issn><issn>1365-2672</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1LxDAQhoMofh_8A1LwoodqvrM9LoufKIKo15KmE83SJrXZqvvvjVY9COYyYXjmYZgXoT2Cj0l6J3PdHhOmqFxBm4RJkVOp6OrXn-cCK7qBtmKcY0wYFnIdbdCCM0K53EThDkxoK-e1X2TT7v3yMev6sADnM_DP2huIY8Ms3CtkYK0z2iwz_aSdj2kk9X2otHFNMyS0gaEPnYehDd5pyJKndQYy7eusc09xB61Z3UTY_a7b6OHs9H52kV_fnl_Opte5YYLJvICKFIIXWnNhYYJVzS1mwqi6Mqbgwkhha1AFlSAoqQirJpxToYQlNSPasm10OHrT8i8DxEXZumigabSHMMSSpmNwPOFkktCDP-g8DL1P2yWKSamYVJ_U0UiZPsTYgy273rW6X5YEl58plCmF8iuFxO5_G4eqhfqX_Dl7Ak5G4M01sPzfVF5Nb0blB4nykcc</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Wu, H.‐C.</creator><creator>Yeh, P.‐H.</creator><creator>Hsueh, K.‐J.</creator><creator>Yang, W.‐J.</creator><creator>Chu, C.‐Y.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TM</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5625-8815</orcidid></search><sort><creationdate>201806</creationdate><title>Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs</title><author>Wu, H.‐C. ; Yeh, P.‐H. ; Hsueh, K.‐J. ; Yang, W.‐J. ; Chu, C.‐Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-9eb19549aa45fe807d4f035c7dbcc945c65fde7926e521b13b8442575f1d31af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Actinobacillus Infections - immunology</topic><topic>Actinobacillus Infections - microbiology</topic><topic>Actinobacillus Infections - prevention & control</topic><topic>Actinobacillus Infections - veterinary</topic><topic>Actinobacillus pleuropneumoniae</topic><topic>Actinobacillus pleuropneumoniae - genetics</topic><topic>Actinobacillus pleuropneumoniae - immunology</topic><topic>Animals</topic><topic>Antibodies, Bacterial - immunology</topic><topic>Antigens</topic><topic>Bacterial Proteins - administration & dosage</topic><topic>Bacterial Proteins - genetics</topic><topic>Bacterial Proteins - immunology</topic><topic>Bacterial Vaccines - administration & dosage</topic><topic>Bacterial Vaccines - genetics</topic><topic>Bacterial Vaccines - immunology</topic><topic>Bacterins</topic><topic>Combined vaccines</topic><topic>Cytometry</topic><topic>Disease control</topic><topic>diseases</topic><topic>Effectiveness</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Homology</topic><topic>Immune response</topic><topic>Immune response (cell-mediated)</topic><topic>Immune system</topic><topic>Lesions</topic><topic>Mice</topic><topic>Outer membrane proteins</topic><topic>Proteins</topic><topic>recombinant protein</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - immunology</topic><topic>Swine</topic><topic>Swine Diseases - immunology</topic><topic>Swine Diseases - microbiology</topic><topic>Swine Diseases - prevention & control</topic><topic>toxins</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, H.‐C.</creatorcontrib><creatorcontrib>Yeh, P.‐H.</creatorcontrib><creatorcontrib>Hsueh, K.‐J.</creatorcontrib><creatorcontrib>Yang, W.‐J.</creatorcontrib><creatorcontrib>Chu, C.‐Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of applied microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, H.‐C.</au><au>Yeh, P.‐H.</au><au>Hsueh, K.‐J.</au><au>Yang, W.‐J.</au><au>Chu, C.‐Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs</atitle><jtitle>Journal of applied microbiology</jtitle><addtitle>J Appl Microbiol</addtitle><date>2018-06</date><risdate>2018</risdate><volume>124</volume><issue>6</issue><spage>1366</spage><epage>1376</epage><pages>1366-1376</pages><issn>1364-5072</issn><eissn>1365-2672</eissn><abstract>Aims
Available bacterins, commercial or autogenous, for Actinobacillus pleuropneumoniae disease control have, thus far, shown debatable protective efficacy and only in homologous challenges. Our study sought to determine whether the addition of reombinant protein ApxIV to the multicomponent vaccine could enhance protection against homologous and heterologous challenge of A. pleuropneumoniae.
Methods and Results
The virulence of ApxI, ApxII, ApxIV and OMP were cloned and expressed using a prokaryotic system; these recombinant proteins were combined with inactivated A. pleuropneumoniae serovar 1 to formulate different multicomponent vaccines. Immune response and protective efficacy of the vaccines were evaluated in mice and pigs. A protection rate of 67% was observed against heterologous challenge in mice vaccinated with the rApxIV formulation. Piglets vaccinated with vaccine containing ApxIV produced significantly higher antibody titre and provided complete protection and reduced gross lesions by 67% when compared with the nonimmunized group after homologous challenge. Additionally, flow cytometry analysis showed significant cellular immune response.
Conclusions
The results of our vaccination experiments revealed that a combination of inactivated bacteria and the recombinant antigens rApxI, rApxII, rApxIV and rOMP can provide effective protection against heterologous A. pleuropneumoniae challenge.
Significance and Impact of the Study
The addition of ApxIV to the multicomponent vaccine could enhance homologous and heterologous protection in mice and pigs, respectively, against challenge by A. pleuropneumoniae.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>29431246</pmid><doi>10.1111/jam.13726</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5625-8815</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1364-5072 |
| ispartof | Journal of applied microbiology, 2018-06, Vol.124 (6), p.1366-1376 |
| issn | 1364-5072 1365-2672 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2001408418 |
| source | MEDLINE; Access via Wiley Online Library; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Actinobacillus Infections - immunology Actinobacillus Infections - microbiology Actinobacillus Infections - prevention & control Actinobacillus Infections - veterinary Actinobacillus pleuropneumoniae Actinobacillus pleuropneumoniae - genetics Actinobacillus pleuropneumoniae - immunology Animals Antibodies, Bacterial - immunology Antigens Bacterial Proteins - administration & dosage Bacterial Proteins - genetics Bacterial Proteins - immunology Bacterial Vaccines - administration & dosage Bacterial Vaccines - genetics Bacterial Vaccines - immunology Bacterins Combined vaccines Cytometry Disease control diseases Effectiveness Female Flow cytometry Homology Immune response Immune response (cell-mediated) Immune system Lesions Mice Outer membrane proteins Proteins recombinant protein Recombinant Proteins - administration & dosage Recombinant Proteins - genetics Recombinant Proteins - immunology Swine Swine Diseases - immunology Swine Diseases - microbiology Swine Diseases - prevention & control toxins Vaccination Vaccines Virulence |
| title | Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T18%3A33%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20ApxIV%20protein%20enhances%20protective%20efficacy%20against%20Actinobacillus%20pleuropneumoniae%20in%20mice%20and%20pigs&rft.jtitle=Journal%20of%20applied%20microbiology&rft.au=Wu,%20H.%E2%80%90C.&rft.date=2018-06&rft.volume=124&rft.issue=6&rft.spage=1366&rft.epage=1376&rft.pages=1366-1376&rft.issn=1364-5072&rft.eissn=1365-2672&rft_id=info:doi/10.1111/jam.13726&rft_dat=%3Cproquest_cross%3E2036673678%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2036673678&rft_id=info:pmid/29431246&rfr_iscdi=true |